V-POINT study

JRCT ID: jRCTs041200045

Registered date:16/09/2020

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Gastric adenoma or early gastric cancer
• Date of first enrollment: 16/09/2020
• Target sample size: 124
• Study type: Interventional
• Intervention(s): Randomization of oral vonoprazan 20mg/day, 8 weeks or esomeprazole 20mg/day, 8 weeks

Outcome(s)

• Primary Outcome: Incidence of bleeding within 8 weeks after ESD.

Secondary Outcome

1. Frequency of GERD-like symptoms after ESD.
2. Frequency of pain after ESD.
3. Healing of the ulcer at 8 weeks after ESD.
4. Adverse events related to ESD.

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: Gastric adenoma or early gastric cancer patients planned for treatment by ESD, and those who take antithrombotics.
• Exclude criteria: Those with simultaneous esophageal or duodenal endoscopic treatment.

Related Information

• Primary Sponsor: Furukawa Kazuhiro
• Secondary ID(s): UMIN000040641